Literature DB >> 11408150

Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

E L LeCluyse1.   

Abstract

Primary cultures of human hepatocytes have been used extensively by both academic and industrial laboratories for evaluating the hepatic disposition of drugs and other xenobiotics. Their primary utility has been for assessing the induction potential of new chemical entities (NCEs) and they continue to serve as the gold standard. Primary considerations for conducting in vitro drug testing utilizing cultures of human hepatocytes, such as the effects of culture and study conditions, are discussed. The maintenance of normal cellular physiology and intercellular contacts in vitro is of particular importance for optimal phenotypic gene expression and response to drugs and other xenobiotics. Significant advances in our understanding of cytochrome P450 (CYP450) enzyme regulation have been made with the recent identification of the nuclear receptors mediating the induction of CYP2B and CYP3A enzymes. In particular, the activation of pregnane X receptor (PXR) by prototypical inducers of CYP3A has been found to correlate well with the species-specific modulation of CYP3A by various drugs and other xenobiotics. Concomitant with the discovery of PXR has been the identification of compounds that may act synergistically or antagonistically on multiple receptors (e.g., co-repressors and/or co-activators of the receptor) introducing novel mechanisms of drug-drug interactions. Differential expression of the individual isoforms of the major CYP450 enzymes over time in culture suggest that this model system is not reflective of in vivo profiles and, therefore, may be limited in its application for drug metabolism studies. Overall, primary cultures of human hepatocytes can serve as a sensitive and selective model for predicting the regulation of CYP450 modulation by drugs and other xenobiotics. Considerations and recommendations for standardizing testing conditions and choosing relevant endpoint(s) are presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408150     DOI: 10.1016/s0928-0987(01)00135-x

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  94 in total

1.  Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicity.

Authors:  Stephanie M Martinez; Blair U Bradford; Valerie Y Soldatow; Oksana Kosyk; Amelia Sandot; Rafal Witek; Robert Kaiser; Todd Stewart; Kirsten Amaral; Kimberly Freeman; Chris Black; Edward L LeCluyse; Stephen S Ferguson; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2010-09-24       Impact factor: 4.219

Review 2.  Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity.

Authors:  Stephen C Strom; Julio Davila; Markus Grompe
Journal:  Methods Mol Biol       Date:  2010

3.  Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Authors:  Kajsa P Persson; Susanne Ekehed; Charlotta Otter; E S Mareike Lutz; Jane McPheat; Collen M Masimirembwa; Tommy B Andersson
Journal:  Pharm Res       Date:  2006-11-22       Impact factor: 4.200

4.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

Review 5.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 6.  In vitro platforms for evaluating liver toxicity.

Authors:  Shyam Sundhar Bale; Lawrence Vernetti; Nina Senutovitch; Rohit Jindal; Manjunath Hegde; Albert Gough; William J McCarty; Ahmet Bakan; Abhinav Bhushan; Tong Ying Shun; Inna Golberg; Richard DeBiasio; Berk Osman Usta; D Lansing Taylor; Martin L Yarmush
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-24

7.  Long-term culture of primary hepatocytes: new matrices and microfluidic devices.

Authors:  Britta Burkhardt; Juan José Martinez-Sanchez; Anastasia Bachmann; Ruth Ladurner; Andreas K Nüssler
Journal:  Hepatol Int       Date:  2013-11-21       Impact factor: 6.047

8.  Long-term culture and characterization of patient-derived primary hepatocytes using conditional reprogramming.

Authors:  Shan Su; Cristina Di Poto; Rabindra Roy; Xuefeng Liu; Wanxing Cui; Alexander Kroemer; Habtom W Ressom
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-11

9.  Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes.

Authors:  Li-Qun Yang; Wei-Feng Yu; Yun-Fei Cao; Bin Gong; Qing Chang; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

10.  In vitro models for liver toxicity testing.

Authors:  Valerie Y Soldatow; Edward L Lecluyse; Linda G Griffith; Ivan Rusyn
Journal:  Toxicol Res (Camb)       Date:  2012-11-23       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.